Search

Your search keyword '"Pajon, Eduardo R"' showing total 21 results
Start Over Author "Pajon, Eduardo R"
21 results on '"Pajon, Eduardo R"'

1. Data from Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

Author

Vogel, Victor G., primary, Costantino, Joseph P., primary, Wickerham, D. Lawrence, primary, Cronin, Walter M., primary, Cecchini, Reena S., primary, Atkins, James N., primary, Bevers, Therese B., primary, Fehrenbacher, Louis, primary, Pajon, Eduardo R., primary, Wade, James L., primary, Robidoux, André, primary, Margolese, Richard G., primary, James, Joan, primary, Runowicz, Carolyn D., primary, Ganz, Patricia A., primary, Reis, Steven E., primary, McCaskill-Stevens, Worta, primary, Ford, Leslie G., primary, Jordan, V. Craig, primary, and Wolmark, Norman, primary

Published
2023
Full Text
View/download PDF

2. Perspectives on this Article from Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

Author

Vogel, Victor G., primary, Costantino, Joseph P., primary, Wickerham, D. Lawrence, primary, Cronin, Walter M., primary, Cecchini, Reena S., primary, Atkins, James N., primary, Bevers, Therese B., primary, Fehrenbacher, Louis, primary, Pajon, Eduardo R., primary, Wade, James L., primary, Robidoux, André, primary, Margolese, Richard G., primary, James, Joan, primary, Runowicz, Carolyn D., primary, Ganz, Patricia A., primary, Reis, Steven E., primary, McCaskill-Stevens, Worta, primary, Ford, Leslie G., primary, Jordan, V. Craig, primary, and Wolmark, Norman, primary

Published
2023
Full Text
View/download PDF

3. Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2 − Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

Author

Rastogi, Priya, Buyse, Marc E., Swain, Sandra M., Jacobs, Samuel A., Robidoux, André, Liepman, Marcia K., Pajon, Eduardo R., Dy, Philip A., Posada, Juan G., Jr, Melnik, Marianne K., Piette, Fanny, Geyer, Charles E., Jr, Mamounas, Elfetherios P., and Wolmark, Norman

Published
2011
Full Text
View/download PDF

5. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

Author

Siziopikou, Kalliopi P., Anderson, Stewart J., Cobleigh, Melody A., Julian, Thomas B., Arthur, Douglas W., Zheng, Ping, Mamounas, Eleftherios P., Pajon, Eduardo R., Behrens, Robert J., Eakle, Janice F., Leasure, Nick C., Atkins, James N., Polikoff, Jonathan A., Seay, Thomas E., McCaskill-Stevens, Worta J., Rabinovitch, Rachel, Costantino, Joseph P., and Wolmark, Norman

Published
2013
Full Text
View/download PDF

6. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

Author

Swain, Sandra M., Jong-Hyeon, Jeong, Geyer, Charles E. Jr, Costantino, Joseph P., Pajon, Eduardo R., Fehrenbacher, Louis, Atkins, James N., Polikoff, Jonathan, Vogel, Victor G., Erban, John K., Rastogi, Priya, Livingston, Robert P., Perez, Edith A., Mamounas, Eleftherios, P., Land, Stephanie R., Ganz, Patricia A., and Wolmark, Norman

Subjects
Docetaxel -- Comparative analysis, Docetaxel -- Health aspects, Breast cancer -- Drug therapy, Doxorubicin -- Comparative analysis, Doxorubicin -- Health aspects, Chemotherapy -- Evaluation, Amenorrhea -- Causes of, Cancer -- Chemotherapy, Cancer -- Evaluation
Abstract

A study was conducted to evaluate and compare the efficacy of concurrent docetaxel (ACT) versus sequential regimens of ACT on survival rate in early breast cancer. Results indicated that sequential ACT far greatly improved disease free survival as well as overall survival rate in the case of such patients.

Published
2010

7. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial

Author

Land, Stephanie R., Ganz, Patricia A., Wickerham, D. Lawrence, Constantino, Joseph P., Lockhart, James B., Jr., Wolmark, Norman, Ritter, Marcie W., Wade, James L., III., Dakhil, Shaker, Vogel, Victor G., Lee, Myoungkeun, and Pajon, Eduardo R.

Subjects
United States
Abstract

A study is conducted to compare the differences in patient-reported outcomes, quality of life (QOL) and symptoms in Study of Tamoxifen and Raloxifene (STAR) participants by treatment assignment. The results reveal that no significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health, mental health and depression, although the tamoxifen group reported better sexual function.

Published
2006

8. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes

Author

Vogel, Victor G., Ford, Leslie G., Jordan, V. Craig, Wolmark, Norman, Constantino, Joseph P., Margolese, Richard G., James, Joan, Lippman, Scott M., Runowicz, Carolyn D., Wickerham, D. Lawrence, Wade, James L., III., Robidoux, Andre, Ganz, Patricia A., Reis, Steven E., McCaskill-Stevens, Worta, Cronin, Walter M., Fehrenbacher, Louis, Pajon, Eduardo R., Jr., Cecchini, Reea S., Atkins, James N., and Bevers, Therese B.

Subjects
United States
Abstract

A study is conducted to compare the relative effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast cancer and other disease outcomes. The results reveal that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has lower risk of thormboembolic events and cataracts but nonstatistically significant higher risk of noninvasive breast cancer.

Published
2006

9. Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

Author

Rastogi, Priya, Buyse, Marc E., Swain, Sandra M., Jacobs, Samuel A., Robidoux, André, Liepman, Marcia K., Pajon, Eduardo R., Dy, Philip A., Posada, Juan G., Melnik, Marianne K., Piette, Fanny, Geyer, Charles E., Mamounas, Elfetherios P., and Wolmark, Norman

Published
2011
Full Text
View/download PDF

10. Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.

Author

Wickerham, Donald Lawrence, primary, Cecchini, Reena S., additional, Vogel, Victor G., additional, Costantino, Joseph P., additional, Cronin, Walter M., additional, Bevers, Therese Bartholomew, additional, Fehrenbacher, Louis, additional, Pajon, Eduardo R., additional, Wade, James Lloyd, additional, Robidoux, Andre, additional, Margolese, Richard G., additional, James, Joan M., additional, Runowicz, Carolyn D., additional, Ganz, Patricia A., additional, Reis, Steven E., additional, McCaskill-Stevens, Worta J., additional, Ford, Leslie G., additional, Jordan, V. Craig, additional, and Wolmark, Norman, additional

Published
2015
Full Text
View/download PDF

11. CHOD/BVAM Chemotherapy and Whole-Brain Radiotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma

Author

Laack, Nadia N., primary, O'Neill, Brian Patrick, additional, Ballman, Karla V., additional, O'Fallon, Judith Rich, additional, Carrero, Xiomara W., additional, Kurtin, Paul J., additional, Scheithauer, Bernd W., additional, Brown, Paul D., additional, Habermann, Thomas M., additional, Colgan, Joseph P., additional, Gilbert, Mark R., additional, Hawkins, Roland B., additional, Morton, Roscoe F., additional, Windschitl, Harry E., additional, Fitch, Tom R., additional, and Pajon, Eduardo R., additional

Published
2011
Full Text
View/download PDF

12. Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial

Author

Ganz, Patricia A., primary, Land, Stephanie R., additional, Geyer, Charles E., additional, Cecchini, Reena S., additional, Costantino, Joseph P., additional, Pajon, Eduardo R., additional, Fehrenbacher, Louis, additional, Atkins, James N., additional, Polikoff, Jonathan A., additional, Vogel, Victor G., additional, Erban, John K., additional, Livingston, Robert B., additional, Perez, Edith A., additional, Mamounas, Eleftherios P., additional, Wolmark, Norman, additional, and Swain, Sandra M., additional

Published
2011
Full Text
View/download PDF

13. Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

Author

Wolf, Sherry L., primary, Qin, Rui, additional, Menon, Smitha P., additional, Rowland, Kendrith M., additional, Thomas, Sachdev, additional, Delaune, Robert, additional, Christian, Diana, additional, Pajon, Eduardo R., additional, Satele, Daniel V., additional, Berenberg, Jeffrey L., additional, and Loprinzi, Charles L., additional

Published
2010
Full Text
View/download PDF

14. Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

Author

Swain, Sandra M., primary, Jeong, Jong-Hyeon, additional, Geyer, Charles E., additional, Costantino, Joseph P., additional, Pajon, Eduardo R., additional, Fehrenbacher, Louis, additional, Atkins, James N., additional, Polikoff, Jonathan, additional, Vogel, Victor G., additional, Erban, John K., additional, Rastogi, Priya, additional, Livingston, Robert B., additional, Perez, Edith A., additional, Mamounas, Eleftherios P., additional, Land, Stephanie R., additional, Ganz, Patricia A., additional, and Wolmark, Norman, additional

Published
2010
Full Text
View/download PDF

15. Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

Author

Mamounas, Eleftherios P., primary, Jeong, Jong-Hyeon, additional, Wickerham, D. Lawrence, additional, Smith, Roy E., additional, Ganz, Patricia A., additional, Land, Stephanie R., additional, Eisen, Andrea, additional, Fehrenbacher, Louis, additional, Farrar, William B., additional, Atkins, James N., additional, Pajon, Eduardo R., additional, Vogel, Victor G., additional, Kroener, Joan F., additional, Hutchins, Laura F., additional, Robidoux, André, additional, Hoehn, James L., additional, Ingle, James N., additional, Geyer, Charles E., additional, Costantino, Joseph P., additional, and Wolmark, Norman, additional

Published
2008
Full Text
View/download PDF

16. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Author

Rastogi, Priya, primary, Anderson, Stewart J., additional, Bear, Harry D., additional, Geyer, Charles E., additional, Kahlenberg, Morton S., additional, Robidoux, André, additional, Margolese, Richard G., additional, Hoehn, James L., additional, Vogel, Victor G., additional, Dakhil, Shaker R., additional, Tamkus, Deimante, additional, King, Karen M., additional, Pajon, Eduardo R., additional, Wright, Mary Johanna, additional, Robert, Jean, additional, Paik, Soonmyung, additional, Mamounas, Eleftherios P., additional, and Wolmark, Norman, additional

Published
2008
Full Text
View/download PDF

17. Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07

Author

Land, Stephanie R., primary, Kopec, Jacek A., additional, Cecchini, Reena S., additional, Ganz, Patricia A., additional, Wieand, H. Samuel, additional, Colangelo, Linda H., additional, Murphy, Kate, additional, Kuebler, J. Philip, additional, Seay, Thomas E., additional, Needles, Burton M., additional, Bearden, James D., additional, Colman, Lauren K., additional, Lanier, Keith S., additional, Pajon, Eduardo R., additional, Cella, David, additional, Smith, Roy E., additional, O'Connell, Michael J., additional, Costantino, Joseph P., additional, and Wolmark, Norman, additional

Published
2007
Full Text
View/download PDF

18. Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Author

Land, Stephanie R., primary, Wickerham, D Lawrence, additional, Costantino, Joseph P., additional, Ritter, Marcie W., additional, Vogel, Victor G., additional, Lee, Myoungkeun, additional, Pajon, Eduardo R., additional, Wade, James L., additional, Dakhil, Shaker, additional, Lockhart, James B., additional, Wolmark, Norman, additional, and Ganz, Patricia A., additional

Published
2006
Full Text
View/download PDF

19. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Author

Vogel, Victor G., primary, Costantino, Joseph P., additional, Wickerham, D Lawrence, additional, Cronin, Walter M., additional, Cecchini, Reena S., additional, Atkins, James N., additional, Bevers, Therese B., additional, Fehrenbacher, Louis, additional, Pajon, Eduardo R., additional, Wade, James L., additional, Robidoux, Andr??, additional, Margolese, Richard G., additional, James, Joan, additional, Lippman, Scott M., additional, Runowicz, Carolyn D., additional, Ganz, Patricia A., additional, Reis, Steven E., additional, McCaskill-Stevens, Worta, additional, Ford, Leslie C., additional, Jordan, V Craig, additional, and Wolmark, Norman, additional

Published
2006
Full Text
View/download PDF

20. A pilot study of long-acting octreotide for symptomatic malignant ascites.

Author

Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, and Hartmann LC

Subjects
Adult, Aged, Aged, 80 and over, Ascites metabolism, Ascites pathology, Female, Humans, Male, Middle Aged, Octreotide adverse effects, Peritoneal Neoplasms metabolism, Peritoneal Neoplasms pathology, Pilot Projects, Quality of Life, Vascular Endothelial Growth Factor A antagonists & inhibitors, Vascular Endothelial Growth Factor A metabolism, Ascites drug therapy, Octreotide administration & dosage, Peritoneal Neoplasms drug therapy
Abstract

Background: Effective, non-invasive, palliative strategies for symptomatic malignant ascites are unavailable. This trial explored whether octreotide, an inhibitor of vascular endothelial growth factor, a putative mediator of ascites, prolongs the interval to next paracentesis., Methods: After a baseline paracentesis and a test of short-acting agent, patients with symptomatic ascites were randomly assigned to long-acting octreotide (Sandostatin LAR®) depot 30 mg intramuscularly every month versus 0.9% sodium chloride administered similarly. Patients were then monitored for recurrent, symptomatic ascites., Results: Thirty-three patients were enrolled: 16 assigned to the octreotide and 17 to the control arm. The median time to next paracentesis was 28 and 14 days in the octreotide and placebo arm, respectively (p = 0.17). After adjustment for extracted ascites volume and abdominal girth change, no statistically significant difference between the groups was observed (hazard ratio = 0.52, with a 95% confidence interval of 0.21-1.28; p = 0.15, per Cox model). Octreotide-treated patients described less of abdominal bloating (p = 0.01), abdominal discomfort (p = 0.02), and shortness of breath (p = 0.007) at one month, although other quality of life symptoms were comparable between the arms. Long-acting octreotide was reasonably well tolerated., Conclusion: As prescribed in this trial, octreotide did not seem effective in prolonging the time to next paracentesis, although improvements in symptoms suggest that vascular endothelial growth factor inhibition merits further investigation., (Copyright © 2012 S. Karger AG, Basel.)

Published
2012
Full Text
View/download PDF

21. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Author

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, and Wolmark N

Subjects
Adenocarcinoma epidemiology, Adenocarcinoma pathology, Adult, Aged, Aged, 80 and over, Breast Neoplasms epidemiology, Breast Neoplasms pathology, Cataract chemically induced, Cataract epidemiology, Double-Blind Method, Drug Utilization, Endometrial Neoplasms chemically induced, Endometrial Neoplasms epidemiology, Female, Follow-Up Studies, Fractures, Spontaneous epidemiology, Fractures, Spontaneous etiology, Fractures, Spontaneous prevention & control, Humans, Incidence, Middle Aged, Myocardial Ischemia epidemiology, Myocardial Ischemia prevention & control, Neoplasm Invasiveness, Neoplasms, Hormone-Dependent epidemiology, Neoplasms, Hormone-Dependent pathology, Osteoporosis, Postmenopausal complications, Osteoporosis, Postmenopausal prevention & control, Raloxifene Hydrochloride adverse effects, Raloxifene Hydrochloride pharmacology, Risk, Selective Estrogen Receptor Modulators adverse effects, Selective Estrogen Receptor Modulators pharmacology, Tamoxifen adverse effects, Tamoxifen pharmacology, Thromboembolism chemically induced, Thromboembolism epidemiology, Uterus pathology, Adenocarcinoma prevention & control, Breast Neoplasms prevention & control, Estrogens, Neoplasms, Hormone-Dependent prevention & control, Raloxifene Hydrochloride therapeutic use, Selective Estrogen Receptor Modulators therapeutic use, Tamoxifen therapeutic use
Abstract

The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events. The FDA approved the SERM raloxifene for breast cancer risk reduction following its demonstrated effectiveness in preventing invasive breast cancer in the Study of Tamoxifen and Raloxifene (STAR). Raloxifene caused less toxicity (versus tamoxifen), including reduced thromboembolic events and endometrial cancer. In this report, we present an updated analysis with an 81-month median follow-up. STAR women were randomly assigned to receive either tamoxifen (20 mg/d) or raloxifene (60 mg/d) for 5 years. The risk ratio (RR; raloxifene:tamoxifen) for invasive breast cancer was 1.24 (95% confidence interval [CI], 1.05-1.47) and for noninvasive disease, 1.22 (95% CI, 0.95-1.59). Compared with initial results, the RRs widened for invasive and narrowed for noninvasive breast cancer. Toxicity RRs (raloxifene:tamoxifen) were 0.55 (95% CI, 0.36-0.83; P = 0.003) for endometrial cancer (this difference was not significant in the initial results), 0.19 (95% CI, 0.12-0.29) for uterine hyperplasia, and 0.75 (95% CI, 0.60-0.93) for thromboembolic events. There were no significant mortality differences. Long-term raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer over time to tamoxifen in preventing noninvasive disease, with far less toxicity (e.g., highly significantly less endometrial cancer). These results have important public health implications and clarify that both raloxifene and tamoxifen are good preventive choices for postmenopausal women with elevated risk for breast cancer., (2010 AACR.)

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results